Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Why tumour markers are not recommended as screening tests

Choosing Wisely Cambodia 2023

Published: 20 Apr 2023

Views: 297

Rating:

Save

Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines

Dr Frederic Ting speaks to ecancer about his talk on the ‘why tumour markers are not recommended as screening tests’ at the "Choosing Wisely Cambodia 2023” congress, held in Phnom Penh on the 18th March 2023.  

He highlights that tumour markers are not as effective as screening tools because of its low diagnostic sensitivity and low specificity.

Related Videos

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate...

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

War in Ukraine: The logistical challenges of transferring medical materials

Dr Horia Vulpe, Dr Ruslan Baltaga

War in Ukraine: The logistical challenges of transferring medical materials ( Dr Horia Vulpe, Dr Ruslan Baltaga )

Choosing Wisely to mitigate financial toxicity in cancer care in Africa

Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Advancing breast cancer diagnosis in the developing world

Dr Hans Junkermann, Prof Dr.Erkin Arıbal and Dr Richard Rainsbury

Advancing breast cancer diagnosis in the developing world ( Dr Hans Junkermann, Prof Dr.Erkin Arıbal and Dr Richard Rainsbury )

More from ecancer